The CytoTracker®

CytoTracker fills the diagnostic gap between patient arrival and lab-based results, enabling immediate immune profiling, confidence in intervention, and optimized patient flow.

CLINICAL IMPACT

Rapid insights that change outcomes.

CytoTracker delivers rapid immune insights at the point of care, giving clinicians the clarity to act earlier, treat smarter, and manage infections with greater confidence.

Early Detection

Screen infections in minutes for faster action.

Bacterial vs Viral

Differentiate immune responses at the point of care.

Risk Stratification

Identify high-risk and borderline patients with clarity.

Antibiotic Stewardship

Guide smarter use. Reduce misuse.

SECOND GENERATION

CytoTracker™ Leukometer™

The device is designed to capture and report essential blood parameters that provide a clear snapshot of immune status, supporting clinicians in rapidly assessing acute infection risk and overall patient health.


— Total White Blood Count


— Absolute Neutrophil Count


— Absolute Lymphocyte Count


Pre-sub meeting w/FDA 2023.
CytoTracker™️ – 510(k) pending. Not available for sale. Expected sales start in 2026.

CytoTracker™ BV (w/AI)

The device evaluates patterns in white blood cell counts to assess whether an infection is more likely viral or bacterial.

²Pre-sub meeting w/FDA 2024

FIRST GENERATION

Point-of-care in action.

Everything you need to know.

Interested in piloting CytoTracker?
Join our early adopter program.